Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
In recent years, there has been a great improvement in the knowledge of the biological aspects of malignant gliomas of the brain. Conversely, there has been an increase of interest in the multimodal treatment of these tumours. In this review, we have analyzed the results of the several reports which have appeared in the literature that deal with the chemotherapeutic treatment of malignant gliomas. Furthermore, some areas of biological investigation that could have an impact on pharmacological therapy are discussed.
Paoletti
P
P
Dipartimento di Chirurgia-Neurochirurgia e Centro E. Grossi-Paoletti, Università di Pavia, Italy.
Butti
G
G
Knerich
R
R
Gaetani
P
P
Assietti
R
R
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use*; D016227:Benzoquinones; D001932:Brain Neoplasms / Q000188:drug therapy*; D002330:Carmustine / Q000627:therapeutic use*; D053138:Cyclohexenes; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; D053138:Cyclohexenes; D008130:Lomustine; C006052:2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone; D002330:Carmustine